4488-59-9

In this study, we screened a large library of (+)-camphor and (?)-borneol derivatives to assess their filovirus entry inhibition activities using pseudotype systems. Structure-activity relationship studies revealed several compounds exhibiting submicromolar IC50 values. These compounds were evaluated for their effect against natural Ebola virus (EBOV) and Marburg virus. Compound 3b (As-358) exhibited the good antiviral potency (IC50 = 3.7 μM, SI = 118) against Marburg virus, while the hydrochloride salt of this compound 3b·HCl had a strong inhibitory effect against Ebola virus (IC50 = 9.1 μM, SI = 31) and good in vivo safety (LD50 > 1000 mg/kg). The results of molecular docking and in vitro mutagenesis analyses suggest that the synthesized compounds bind to the active binding site of EBOV glycoprotein similar to the known inhibitor toremifene.

Provided in the present invention are a phenylpropionate compound, a preparation method for same, and applications. The phenylpropionate compound has the structure as represented by formula I. The phenylpropionate compound of the present invention, a pharmaceutically acceptable salt, a solvate, a prodrug, and a tautomer or stereochemical isomer or pharmaceutical composition of the compound provide improved anti-inflammatory and antiplatelet effects and, at the same time, provide an extended time window for treatment, are free of obvious side effects, safe and effective, applicable in an antithrombus, anti-inflammatory, and cerebral stroke treating medicament, and have broad application prospects.

The invention provides a phenylacrylate compound as well as a preparation method and application thereof. The phenylacrylate compound has the structure shown in a formula I. The phenylacrylate compound and pharmaceutically acceptable salt, solvent compound, predrug, tautomer or stereoisomer or medicinal composition thereof have good anti-inflammatory and antiplatelet effects, have a long treatmenttime window, do not have remarkable side effect, is safe and effective, can serve as antithrombus, anti-inflammatory and stroke-treating medicines and have wide application prospects.

Herein, we present the design and synthesis of a series of novel heterocyclic derivatives of (-)-borneol and (-)-isoborneol as potent inhibitors of the influenza A virus. All compounds were tested for their toxicity against MDCK cells and for virus-inhibiting activity against the influenza virus A/Puerto Rico/8/34 (H1N1). Compounds 7, 16 and 26 containing a morpholine fragment exhibited the highest efficiency as agents inhibiting the replication of the influenza virus A(H1N1) with selectivity indices of 82, 45 and 65, correspondingly. Derivatives 9 (SI = 23) and 18 (SI = 25) containing a 1-methylpiperazine motif showed moderate antiviral activity. Structure-activity analysis of this new series of borneol derivatives revealed that a 1,7,7-trimethylbicyclo[2.2.1]heptan scaffold is required for the antiviral activity.

(figure presented) A series of novel heterocyclic derivatives of (–)-borneol has been prepared by the interaction of (1S,2R,4S)-1,7,7-trimethylbicyclo[2.2.1]-heptan-2-yl 2-chloroacetate and (1S,2R,4S)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl 3-chloropropanoate with different N- and S-nucleophiles. The obtained products were screened for antiviral, antiulcer, and analgesic activity.

Novel chiral ionic liquids having chirality in their cationic part have been synthesized for evaluation of their catalytic potential as organocatalysts in sodium borohydride reduction of prochiral ketones to yield optically active secondary alcohols. The chiral ionic liquids have been synthesized from the reaction of (?)-menthol or (?)-borneol, chloroacetic acid and S-methyl/benzyl-2-mercaptobenzthiazole. The synthesized chiral ionic liquids have been characterized by 1H, 13C NMR and Mass spectrometry. Moderate to excellent enantiomeric excess (ee?>?99%) has been obtained in asymmetric sodium borohydride reduction of prochiral ketones using these salts as chiral catalysts.

New chiral ionic liquids based on benzimidazolium salts have been synthesized from the reaction of (-)-menthol or (-)-borneol, chloroacetic acid and 1-methylbenzimidazole. The structures of these chiral ionic liquids have been confirmed from 1H

The invention relates to a synthesis method of racemic bornyl beta-(3,4-dihydroxyphenyl)-alpha-hydroxypropionate. The method comprises the following steps: carrying out Darzens epoxidation on an initial raw material benzyl protected protocatechualdehyde, and carrying out palladium catalyst/hydrogen or Raney nickel/hydrogen catalytic reduction to obtain racemic bornyl beta-(3,4-dihydroxyphenyl)-alpha-hydroxypropionate. The purity and the yield of a product synthesized by adopting the method reach 98% and 48.6% respectively. The synthesis method has the advantages of simple and easily available raw material, short route, high yield, and suitableness for large scale industrialized production.

New molybdenum complexes of the type [CpMo(CO)3X] containing ligands of the formula X = CHR2CO(OR1) where R1 = ethyl (1), menthyl (4), and bornyl (5) and R2 = H; R1 = ethyl and R2 = methyl (2) and phenyl (3) have been synthesized and characterized by NMR and IR spectroscopy and X-ray crystallography. These compounds have been applied as catalyst precursors for achiral and chiral epoxidation of unfunctionalized olefins with tert-butyl hydroperoxide (TBHP) as the oxidant at 22 °C (in CH2Cl2) and 55°C (in CHCl3). The substrates cis-cyclooctene, 1-octene, cis- and trans-stilbene, and trans-β-methylstyrene were selectively and quantitatively converted into their epoxides using a catalyst:substrate:oxidant ratio of 1:100:200 within 4 h at room temperature in CH2Cl2 and within 15 min at 55°C in CHCl3. Complexes 1-5 are precursors of active epoxidation catalysts and turnover frequencies (TOFs) of ca. 1200 h-1 are obtained with cis-cyclooctene as the substrate. No enantioselectivity is observed with trans-β-methylstyrene as the substrate despite the application of enantiomerically pure precatalysts. In situ monitoring of catalytic epoxidation of cis-cyclooctene with complex 5 by 1H and 13C NMR spectroscopy suggests that the chiral alkyl ester side chain is retained during oxidation with TBHP. During epoxidation, the primary catalytic species is the dioxo complex [CpMoO2X]. After near complete conversion of cis-cyclooctene to its epoxide, further oxidation of the dioxo complex to oxo-peroxo complex [CpMo(η2-O2)(O)X] takes place. The oxo-peroxo complex is also an active epoxidation catalyst.

Several ionic liquids containing a chiral center either in the cation or in the anion have been prepared. They have been applied as catalysts and solvents for stereoselective oxidation of methyl phenyl sulfide to obtain the respective sulfoxide.

Asymmetric thia-Diels-Alder reactions involving new dithioesters bearing a chiral auxiliary are described, with diastereoselectivities up to 78%. Double-stereodifferentiating experiments employing chiral substrates in the presence of a chiral Lewis acid c

The present invention provides with a process of preparing an optically active succinimide derivative, which is a key intermediate for production of ranirestat. A compound (3) is easily prepared by treating the derivative of succinic acid diester of the formula (2): wherein R1 is an amino group protected with a group removed by hydrogenolysis or a tert-butoxycarbonylamino group and R2 is an ethyl group optionally substituted with one or two methyl group(s) at α-position, provided that R2 is not a tert-butyl group when R1 is a tert-butoxycarbonylamino group; with alkali metal alkoxide and the compound (3) can be an important intermediate for production of ranirestat.

New chiral ionic liquids (CILs) based on (-)-menthol and (-)-borneol were designed and synthesized in very good yields using a simple and efficient 3-step strategy. The properties and characterization of these compounds are discussed.

One aspect of the present invention relates to cinchona-alkaloid-based catalysts. A second aspect of the invention relates to a method of preparing a derivatized cinchona alkaloid catalyst by reacting a cinchona-alkaloid with base and a compound that has a suitable leaving group. Another aspect of the present invention relates to a method of preparing a chiral, non-racemic compound from a prochiral cyclic anhydride or a meso cyclic anhydride, comprising the step of: reacting a prochiral cyclic anhydride or a meso cyclic anhydride with a nucleophile in the presence of a catalyst; wherein said prochiral cyclic anhydride or meso cyclic anhydride comprises an internal plane of symmetry or point of symmetry or both; thereby producing a chiral, non-racemic compound; wherein said catalyst is a derivatized cinchona-alkaloid. Yet another aspect of the present invention relates to a method of kinetic resolution, comprising the step of: reacting a racemic cyclic anhydride with an alcohol in the presence of a derivatized cinchona-alkaloid catalyst.

Reaction of chloroacetic acid with TPP-DEAD was found to be very effective for the inversion of sterically congested alcohols, including carbohydrates and nucleosides.

High yield syntheses of one chiral sulfonyloxyiminomalononitrile and four alkyl sulfonyloxyimonocyanoacetate derivatives (3a-e), to be used in asymmetric hetero-Diels-Alder additions, are described.

1-Carboxy-(alkanoyl or aralkanoyl)-indoline-2-carboxylic acids, e.g., those of the formula STR1 R=H, alkyl, alkoxy, halogeno or CF3 ; R'=H or R-phenyl; m=0 or 1; p,q=0 to 2; and derivatives thereof, are antihypertensive and cardioactive agents.